 |
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|
   |
| ONCX Continues to Keep its Promises Submits Application for Listing on OTCQB |
|
 Hot Stock to Watch |
Company: Oncolix, Inc. (Pink Sheets: ONCX)
|
Last:
Price: 0.0499
Change (%): + 0.0029 (6.17)
Volume: 105,803 |
 |
Oncolix, Inc., Announces Submission of Application for Listing on OTC-QB
OTC-QB listing anticipated to be finalized before the end of the year
HOUSTON, Dec. 06, 2017 (GLOBE NEWSWIRE) - Oncolix, Inc., (OTC PINK:ONCX) announced today that following the appointment of the second independent member of the Board of Directors the Company has fulfilled the requirements and has submitted an application to be listed on the OTC-QB. The review is anticipated to take approximately two to four weeks after which Oncolix would be listed on the OTC-QB.
“We continue to make progress building out our public biopharmaceutical company infrastructure and today, we are finally able to realize an important step by submitting the application for listing on the OTC-QB,” said Michael T. Redman, chief executive officer of Oncolix. “We continue to meet our announced milestones, most recently changing the company name and stock ticker, appointing two independent members to our board of directors, and finishing an extensive review process by the Financial Industry Regulatory Authority (FINRA). All of these actions are directed toward our ultimate objective of a NASDAQ listing.”
About Oncolix
Oncolix is a clinical-stage biotechnology company developing Prolanta™ for the treatment of ovarian, uterine, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in its first indication, the treatment of ovarian cancer. This Phase 1 clinical trial is currently in progress. Prolanta™ is a prolactin receptor antagonist (or blocker) that has demonstrated efficacy in xenograft models through a unique mechanism of action, autophagy. In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ may be effective in breast, prostate and other cancers. In the current Phase 1 dose-escalation safety trial for the treatment of ovarian cancer, to date there have been no observed serious adverse events and no dose-limiting toxicities. The FDA has approved the designation of Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may result in reduced filing fees (currently 2 million dollars), federal tax credits and marketing exclusivity.
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
